

Miguel Bernardo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1796120/miguel-bernardo-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

380
papers

8,739
citations

45
h-index

75
g-index

448
ext. papers

10,807
ext. citations

3.8
avg, IF

5.74
L-index

#	Paper	IF	Citations
380	Two Factors, Five Factors, or Both? External Validation Studies of Negative Symptom Dimensions in Schizophrenia.. <i>Schizophrenia Bulletin</i> , 2022 ,	1.3	5
379	Impact of traumatic life events on clinical variables of individuals with first-episode psychosis and healthy controls.. <i>International Journal of Social Psychiatry</i> , 2022 , 207640211070398	8.5	
378	Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study.. <i>Psychological Medicine</i> , 2022 , 1-10	6.9	2
377	Is the effect of cognitive reserve in longitudinal outcomes in first-episode psychoses dependent on the use of cannabis?. <i>Journal of Affective Disorders</i> , 2022 , 302, 83-83	6.6	1
376	Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case-Control Study.. <i>Schizophrenia Bulletin</i> , 2022 ,	1.3	1
375	Antipsychotic-Associated Weight Gain and Clinical Improvement Under Clozapine Treatment.. <i>Journal of Clinical Psychopharmacology</i> , 2022 , 42, 75-80	1.7	0
374	Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022 , 113, 110440	5.5	0
373	Cortical thinning over two years after first-episode psychosis depends on age of onset.. <i>NPJ Schizophrenia</i> , 2022 , 8, 20	5.5	0
372	The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study.. <i>European Neuropsychopharmacology</i> , 2022 , 57, 105-117	1.2	
371	Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia.. <i>Schizophrenia Research</i> , 2022 , 243, 32-42	3.6	1
370	Cultural adaptation to Spanish of the “Patient Satisfaction Survey” to assess satisfaction with electroconvulsive therapy (ECT).. <i>Actas Espanolas De Psiquiatria</i> , 2022 , 50, 1-14	0.7	
369	The network structure of cognitive deficits in first episode psychosis patients. <i>Schizophrenia Research</i> , 2022 , 244, 46-54	3.6	0
368	Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort. <i>Schizophrenia Research</i> , 2022 , 244, 101-110	3.6	0
367	Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study. <i>Psychological Medicine</i> , 2021 , 51, 1536-1548	6.9	20
366	A longitudinal study of gene expression in first-episode schizophrenia; exploring relapse mechanisms by co-expression analysis in peripheral blood. <i>Translational Psychiatry</i> , 2021 , 11, 539	8.6	1
365	Relationship between cognition and age at onset of first-episode psychosis: comparative study between adolescents, young adults, and adults. <i>European Child and Adolescent Psychiatry</i> , 2021 , 1	5.5	0
364	Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. <i>Schizophrenia Research</i> , 2021 , 230, 104-107	3.6	5

363	Resilience and mental health during the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2021 , 283, 156-164	6.6	24
362	Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a six-country case-control study. <i>Psychological Medicine</i> , 2021 , 1-9	6.9	3
361	Cognitive heterogeneity in the offspring of patients with schizophrenia or bipolar disorder: a cluster analysis across family risk. <i>Journal of Affective Disorders</i> , 2021 , 282, 757-765	6.6	0
360	Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies. <i>Advances in Therapy</i> , 2021 , 38, 2491-2512	4.1	5
359	The Independent Effects of Psychosocial Stressors on Subclinical Psychosis: Findings From the Multinational EU-GEI Study. <i>Schizophrenia Bulletin</i> , 2021 , 47, 1674-1684	1.3	3
358	Duration of Untreated Psychosis in First-Episode Psychosis is not Associated With Common Genetic Variants for Major Psychiatric Conditions: Results From the Multi-Center EU-GEI Study. <i>Schizophrenia Bulletin</i> , 2021 , 47, 1653-1662	1.3	0
357	The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
356	Identifying clinical clusters with distinct trajectories in first-episode psychosis through an unsupervised machine learning technique. <i>European Neuropsychopharmacology</i> , 2021 , 47, 112-129	1.2	7
355	The functioning assessment short test (FAST) applied to first-episode psychosis: Psychometric properties and severity thresholds. <i>European Neuropsychopharmacology</i> , 2021 , 47, 98-111	1.2	4
354	Self-reported neurocognitive symptoms during COVID-19 lockdown and its associated factors in a sample of psychiatric patients. Results from the BRIS-MHC study. <i>European Neuropsychopharmacology</i> , 2021 , 53, 7-18	1.2	3
353	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2021 , 14, 164-176	0.2	1
352	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. <i>Revista De Psiquiatria Y Salud Mental</i> , 2021 , 14, 164-176	2.7	2
351	Jumping to conclusions, general intelligence, and psychosis liability: findings from the multi-centre EU-GEI case-control study. <i>Psychological Medicine</i> , 2021 , 51, 623-633	6.9	15
350	Effects of the COVID-19 pandemic and lockdown in Spain: comparison between community controls and patients with a psychiatric disorder. Preliminary results from the BRIS-MHC STUDY. <i>Journal of Affective Disorders</i> , 2021 , 281, 13-23	6.6	35
349	The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis. <i>Psychopharmacology</i> , 2021 , 238, 665-676	4.7	3
348	Brain structural trajectories in youth at familial risk for schizophrenia or bipolar disorder according to development of psychosis spectrum symptoms. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2021 , 62, 780-789	7.9	3
347	Difficulties in delivery and depressive symptomatology in schizophrenia. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2021 , 14, 66-68	0.2	
346	Clinical remission in a cohort of first-episode psychosis: Data from the PEPs study. <i>Psiquiatria Biologica</i> , 2021 , 28, 1-8	0.2	

345	Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. <i>European Psychiatry</i> , 2021 , 64, e25	6	6
344	Difficulties in delivery and depressive symptomatology in schizophrenia. <i>Revista De Psiquiatria Y Salud Mental</i> , 2021 , 14, 66-68	2.7	0
343	Migration history and risk of psychosis: results from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2021 , 1-13	6.9	6
342	Trajectories of suicidal ideation after first-episode psychosis: a growth mixture modeling approach. <i>Acta Psychiatrica Scandinavica</i> , 2021 , 143, 418-433	6.5	1
341	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. <i>Translational Psychiatry</i> , 2021 , 11, 423	8.6	1
340	Identification of a Key Gene Involved in Antipsychotic-Induced Metabolic Dysregulation Based on Integrative Bioinformatics Analysis of Multi-Tissue Gene Expression Data. <i>Frontiers in Pharmacology</i> , 2021 , 12, 729474	5.6	
339	The effect of family environment and psychiatric family history on psychosocial functioning in first-episode psychosis at baseline and after 2 years. <i>European Neuropsychopharmacology</i> , 2021 , 49, 54-68 ^{1,2}		3
338	Interindividual variability of functional connectome in schizophrenia. <i>Schizophrenia Research</i> , 2021 , 235, 65-73	3.6	1
337	The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study. <i>Schizophrenia Research</i> , 2021 , 236, 69-79	3.6	0
336	Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis. <i>Schizophrenia Research</i> , 2021 , 236, 19-28	3.6	0
335	Cognitive clusters in first-episode psychosis. <i>Schizophrenia Research</i> , 2021 , 237, 31-39	3.6	0
334	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. <i>Molecular Psychiatry</i> , 2021 , 26, 4529-4543	15.1	7
333	Social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis. <i>European Psychiatry</i> , 2021 , 64, S163-S163	6	
332	P.0149 Cognitive reserve and cannabis use in first-episode psychoses. <i>European Neuropsychopharmacology</i> , 2021 , 53, S107-S108	1.2	
331	The incidence of psychotic disorders among migrants and minority ethnic groups in Europe: findings from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2020 , 1-10	6.9	7
330	Authors' Reply to N on the existence of a linguistic distance in schizophrenia. <i>Psychological Medicine</i> , 2020 , 1-2	6.9	8
329	Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. <i>Psychological Medicine</i> , 2020 , 1-9	6.9	4
328	Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms. <i>Psychopharmacology</i> , 2020 , 237, 2151-2159	4.7	4

327	Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study. <i>Psychological Medicine</i> , 2020 , 1-9	6.9	13
326	Examining Gene-Environment Interactions Using Aggregate Scores in a First-Episode Psychosis Cohort. <i>Schizophrenia Bulletin</i> , 2020 , 46, 1019-1025	1.3	11
325	Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. <i>Journal of Psychopharmacology</i> , 2020 , 34, 514-523	4.6	8
324	The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI): Incidence and First-Episode Case-Control Programme. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2020 , 55, 645-657	4.5	20
323	Intra-individual variation of clozapine and norclozapine plasma levels in clinical practice. <i>Revista De Psiquiatria Y Salud Mental</i> , 2020 , 13, 31-35	2.7	2
322	Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study. <i>Schizophrenia Research</i> , 2020 , 218, 292-294	3.6	1
321	The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory. <i>Psychological Medicine</i> , 2020 , 1-10	6.9	1
320	Exploring Risk and Resilient Profiles for Functional Impairment and Baseline Predictors in a 2-Year Follow-Up First-Episode Psychosis Cohort Using Latent Class Growth Analysis. <i>Journal of Clinical Medicine</i> , 2020 , 10,	5.1	4
319	Predictors of Bipolar Disorder Versus Schizophrenia Diagnosis in a Multicenter First Psychotic Episode Cohort: Baseline Characterization and a 12-Month Follow-Up Analysis. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	4
318	Epigenetic Studies in Psychotherapy: A Systematic Review. <i>Current Psychiatry Research and Reviews</i> , 2020 , 16, 86-92	0.5	
317	Neuropsychological development in the child and adolescent offspring of patients diagnosed with schizophrenia or bipolar disorder: A two-year follow-up comparative study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020 , 103, 109972	5.5	2
316	Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis. <i>Psychological Medicine</i> , 2020 , 50, 2702-2710	6.9	14
315	Elevated Extracellular Free-Water in a Multicentric First-Episode Psychosis Sample, Decrease During the First 2 Years of Illness. <i>Schizophrenia Bulletin</i> , 2020 , 46, 846-856	1.3	2
314	Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort. <i>Acta Psychiatrica Scandinavica</i> , 2020 , 141, 541-552	6.5	5
313	Intra-individual variation of clozapine and norclozapine plasma levels in clinical practice. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2020 , 13, 31-35	0.2	
312	M60. EARLY VERSUS DELAYED PRESCRIPTION OF CLOZAPINE AND THE COGNITIVE PERFORMANCE ON SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020 , 46, S157-S158	1.3	78
311	S47. A MULTICENTER STUDY OF COGNITIVE RESERVE IN FIRST-EPISODE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2020 , 46, S50-S50	1.3	78
310	Spatial Suppression and Sensitivity for Motion in Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2020 , 1,	2.2	3

309	Influence of BDNF and MTHFR polymorphisms on hippocampal volume in first-episode psychosis. <i>Schizophrenia Research</i> , 2020 , 223, 345-352	3.6	2
308	A replication study of JTC bias, genetic liability for psychosis and delusional ideation. <i>Psychological Medicine</i> , 2020 , 1-7	6.9	3
307	Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. <i>European Psychiatry</i> , 2020 , 63, e71	6	9
306	P.530 Intestinal permeability and low-grade chronic inflammation in schizophrenia: do they influence cognition and cognitive reserve?. <i>European Neuropsychopharmacology</i> , 2020 , 40, S297-S298	1.2	
305	P.537 Investigating the clinical features associated with specific family environment styles in first psychotic episodes. <i>European Neuropsychopharmacology</i> , 2020 , 40, S302	1.2	
304	Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. <i>Epidemiology and Psychiatric Sciences</i> , 2020 , 29, e182	5.1	11
303	Electroconvulsive therapy protocol adaptation during the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2020 , 276, 241-248	6.6	17
302	Cognitive remediation and brain connectivity: A resting-state fMRI study in patients with schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2020 , 303, 111140	2.9	4
301	Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. <i>Psychological Medicine</i> , 2020 , 1-13	6.9	2
300	The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses. <i>Psychological Medicine</i> , 2020 , 1-12	6.9	6
299	The role of genetics in cognitive remediation in schizophrenia: A systematic review. <i>Schizophrenia Research: Cognition</i> , 2020 , 19, 100146	2.8	2
298	Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study. <i>Psychological Medicine</i> , 2020 , 50, 1884-1897	6.9	17
297	Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. <i>Schizophrenia Bulletin</i> , 2020 , 46, 517-529	1.3	10
296	White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?. <i>Frontiers in Psychiatry</i> , 2019 , 10, 676	5	1
295	Food craving and consumption evolution in patients starting treatment with clozapine. <i>Psychopharmacology</i> , 2019 , 236, 3317-3327	4.7	3
294	Auditory hallucinations in first-episode psychosis: A voxel-based morphometry study. <i>Schizophrenia Research</i> , 2019 , 209, 148-155	3.6	4
293	Cognitive Reserve Assessment Scale in Health (CRASH): Its Validity and Reliability. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	12
292	Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis. <i>European Neuropsychopharmacology</i> , 2019 , 29, 786-794	1.2	11

291	Antipsychotic-induced weight gain and birth weight in psychosis: A fetal programming model. <i>Journal of Psychiatric Research</i> , 2019 , 115, 29-35	5.2	10
290	Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. <i>World Psychiatry</i> , 2019 , 18, 173-182	14.4	73
289	Are there differences in prodromal symptoms according to the age of onset of psychosis?. <i>European Neuropsychopharmacology</i> , 2019 , 29, S553-S554	1.2	
288	The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. <i>Lancet Psychiatry</i> , 2019 , 6, 427-436	23.3	322
287	CIBERSAM: Ten years of collaborative translational research in mental disorders. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2019 , 12, 1-8	0.2	1
286	Differences in the regulation of inflammatory pathways in adolescent- and adult-onset first-episode psychosis. <i>European Child and Adolescent Psychiatry</i> , 2019 , 28, 1395-1405	5.5	3
285	Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. <i>Revista De Psiquiatría Y Salud Mental</i> , 2019 , 12, 92-105	2.7	11
284	Neutrophil Count Is Associated With Reduced Gray Matter and Enlarged Ventricles in First-Episode Psychosis. <i>Schizophrenia Bulletin</i> , 2019 , 45, 846-858	1.3	15
283	Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2019 , 12, 92-105	0.2	1
282	Early Parental Death and Risk of Psychosis in Offspring: A Six-Country Case-Control Study. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	3
281	Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study. <i>Schizophrenia Bulletin</i> , 2019 , 45, 960-965	1.3	20
280	Effects of electroconvulsive therapy in the systemic inflammatory balance of patients with severe mental disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2019 , 73, 628-635	6.2	10
279	One decade of the first episodes project (PEPs): Advancing towards a precision psychiatry. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2019 , 12, 135-140	0.2	1
278	Age at first episode modulates progressive cortical thinning in individuals with psychosis. <i>European Neuropsychopharmacology</i> , 2019 , 29, S103-S104	1.2	
277	Influence of secondary sources in the Brief Negative Symptom Scale. <i>Schizophrenia Research</i> , 2019 , 204, 452-454	3.6	3
276	Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2019 , 49, 1378-1391	6.9	42
275	Blood cell count in antipsychotic-naive patients with non-affective psychosis. <i>Microbial Biotechnology</i> , 2019 , 13, 95-100	3.3	14
274	Cross-cultural Validation of the 5-Factor Structure of Negative Symptoms in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019 , 45, 305-314	1.3	70

273	Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia. <i>Psychological Medicine</i> , 2018 , 48, 2668-2675	6.9	21
272	Quality indicators in the treatment of patients with depression, bipolar disorder or schizophrenia. Consensus study. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2018 , 11, 66-75	0.2	
271	Smoking does not impact social and non-social cognition in patients with first episode psychosis. <i>Schizophrenia Research</i> , 2018 , 199, 64-74	3.6	12
270	A Case Study of Clozapine and Cognition: Friend or Foe?. <i>Journal of Clinical Psychopharmacology</i> , 2018 , 38, 152-153	1.7	2
269	Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?. <i>Psychological Medicine</i> , 2018 , 48, 2247-2256	6.9	25
268	SiNoPsis: Single Nucleotide Polymorphisms selection and promoter profiling. <i>Bioinformatics</i> , 2018 , 34, 303-305	7.2	1
267	Quality indicators in the treatment of patients with depression, bipolar disorder or schizophrenia. Consensus study. <i>Revista De Psiquiatría Y Salud Mental</i> , 2018 , 11, 66-75	2.7	8
266	Detection of early psychotic symptoms: Validation of the Spanish version of the "Symptom Onset in Schizophrenia (SOS) inventory". <i>Psychiatry Research</i> , 2018 , 261, 68-72	9.9	6
265	BDNF as a marker of response to cognitive remediation in patients with schizophrenia: A randomized and controlled trial. <i>Schizophrenia Research</i> , 2018 , 197, 458-464	3.6	10
264	Inverse association between negative symptoms and body mass index in chronic schizophrenia. <i>Schizophrenia Research</i> , 2018 , 192, 69-74	3.6	15
263	Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. <i>Schizophrenia Research</i> , 2018 , 193, 188-196	3.6	25
262	Relationship Between Antipsychotic Medications and Cerebrovascular Disease in Patients With Serious Mental Illness. <i>Journal of Psychiatric Practice</i> , 2018 , 24, 72-78	1.3	1
261	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. <i>Lancet Psychiatry</i> , 2018 , 5, 797-807	23.3	100
260	Cardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 410-422	5.8	10
259	Cognitive reserve as an outcome predictor: first-episode affective versus non-affective psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2018 , 138, 441-455	6.5	42
258	Affective versus non-affective first episode psychoses: A longitudinal study. <i>Journal of Affective Disorders</i> , 2018 , 238, 297-304	6.6	18
257	Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. <i>JAMA Psychiatry</i> , 2018 , 75, 36-46	14.5	154
256	Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018 , 268, 699-711	5.1	21

255	Obstetric Phenotypes in the Heterogeneity of Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2018 , 206, 882-886	1.8	9
254	Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics. <i>Translational Psychiatry</i> , 2018 , 8, 276	8.6	5
253	The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1623-1629	4	4
252	S69. A CASE STUDY OF CLOZAPINE AND COGNITION: FRIEND OR FOE?. <i>Schizophrenia Bulletin</i> , 2018 , 44, S351-S351	1.3	0
251	F245. COGNITIVE RESERVE DIFFERENCE IN AFFECTIVE AND NONAFFECTIVE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018 , 44, S318-S318	1.3	78
250	Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis. <i>Journal of Psychopharmacology</i> , 2018 , 32, 702-710	4.6	5
249	Thinking About Electroconvulsive Therapy: The Opinions of Parents of Adolescents with Schizophrenia Spectrum Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017 , 27, 75-82	2.9	8
248	Pattern of electroconvulsive therapy use in Spain: Proposals for an optimal practice and equitable access. <i>Revista De Psiquiatría Y Salud Mental</i> , 2017 , 10, 87-95	2.7	6
247	Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. <i>Revista De Psiquiatría Y Salud Mental</i> , 2017 , 10, 4-20	2.7	11
246	Cannabis use, COMT, BDNF and age at first-episode psychosis. <i>Psychiatry Research</i> , 2017 , 250, 38-43	9.9	21
245	Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. <i>Frontiers in Neuroendocrinology</i> , 2017 , 45, 25-34	8.9	30
244	The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. <i>Schizophrenia Research</i> , 2017 , 189, 84-90	3.6	30
243	Gene-environment interaction as a predictor of early adjustment in first episode psychosis. <i>Schizophrenia Research</i> , 2017 , 189, 196-203	3.6	7
242	Metabolic syndrome or glucose challenge in first episode of psychosis?. <i>European Psychiatry</i> , 2017 , 41, 42-46	6	14
241	Modelling gene-environment interaction in first episodes of psychosis. <i>Schizophrenia Research</i> , 2017 , 189, 181-189	3.6	30
240	Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients. <i>European Neuropsychopharmacology</i> , 2017 , 27, 647-656	1.2	12
239	International trends in clozapine use: a study in 17 countries. <i>Acta Psychiatrica Scandinavica</i> , 2017 , 136, 37-51	6.5	120
238	Adherence predicts symptomatic and psychosocial remission in schizophrenia: Naturalistic study of patient integration in the community. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2017 , 10, 149-159	0.2	1

237	Clinical, Cognitive, and Neuroimaging Evidence of a Neurodevelopmental Continuum in Offspring of Proband With Schizophrenia and Bipolar Disorder. <i>Schizophrenia Bulletin</i> , 2017 , 43, 1208-1219	1.3	25
236	When the healthcare does not follow the evidence: The case of the lack of early intervention programs for psychosis in Spain. <i>Revista De Psiquiatría Y Salud Mental</i> , 2017 , 10, 78-86	2.7	25
235	Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2017 , 10, 4-20	0.2	
234	When the healthcare does not follow the evidence: The case of the lack of early intervention programs for psychosis in Spain. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2017 , 10, 78-86	0.2	
233	Protocol for the management of psychiatric patients with psychomotor agitation. <i>BMC Psychiatry</i> , 2017 , 17, 328	4.2	23
232	Neuroimaging studies of cognitive remediation in schizophrenia: A systematic and critical review. <i>World Journal of Psychiatry</i> , 2017 , 7, 34-43	3	23
231	Documento de posicionamiento de consenso por el Colectivo de Psiquiatras por la Actualización de Clozapina. <i>Psiquiatria Biologica</i> , 2017 , 24, 64-66	0.2	2
230	Algorithm-based protocol for the identification, management and treatment of psychiatric patients with acute psychomotor agitation. <i>European Psychiatry</i> , 2017 , 41, S566-S566	6	
229	Pattern of electroconvulsive therapy use in Spain: Proposals for an optimal practice and equitable access. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2017 , 10, 87-95	0.2	
228	International trends in antipsychotic use: A study in 16 countries, 2005-2014. <i>European Neuropsychopharmacology</i> , 2017 , 27, 1064-1076	1.2	112
227	Do FSH/LH ratio and gonadal hormone levels predict clinical improvement in postmenopausal schizophrenia women?. <i>Archives of Women's Mental Health</i> , 2017 , 20, 613-620	5	10
226	Microarray gene-expression study in fibroblast and lymphoblastoid cell lines from antipsychotic-naïve first-episode schizophrenia patients. <i>Journal of Psychiatric Research</i> , 2017 , 95, 91-101	5.2	2
225	Is cerebrovascular disease a silent condition in patients with chronic schizophrenia-related disorders?. <i>International Clinical Psychopharmacology</i> , 2017 , 32, 80-86	2.2	3
224	Adherence predicts symptomatic and psychosocial remission in schizophrenia: Naturalistic study of patient integration in the community. <i>Revista De Psiquiatría Y Salud Mental</i> , 2017 , 10, 149-159	2.7	10
223	Persistent Negative Symptoms in First-Episode Psychosis: Early Cognitive and Social Functioning Correlates and Differences Between Early and Adult Onset. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 1414-1422	4.6	21
222	Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms. <i>Pharmacogenomics Journal</i> , 2016 , 16, 293-305	3.5	5
221	The impact of cognitive reserve in the outcome of first-episode psychoses: 2-year follow-up study. <i>European Neuropsychopharmacology</i> , 2016 , 26, 1638-48	1.2	67
220	Cognition and psychopathology in first-episode psychosis: are they related to inflammation?. <i>Psychological Medicine</i> , 2016 , 46, 2133-44	6.9	28

219	Antipsychotic Response Worsens With Postmenopausal Duration in Women With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2016 , 36, 580-587	1.7	29
218	Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. <i>Pharmacogenomics Journal</i> , 2016 , 16, 439-45	3.5	25
217	Antipsychotic switching in schizoaffective disorder: A systematic review. <i>World Journal of Biological Psychiatry</i> , 2016 , 17, 495-513	3.8	13
216	Dysregulated peripheral endocannabinoid system signaling is associated with cognitive deficits in first-episode psychosis. <i>Journal of Psychiatric Research</i> , 2016 , 75, 14-21	5.2	14
215	A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. <i>International Journal of Neuropsychopharmacology</i> , 2016 , 19,	5.8	21
214	Assessment and management of agitation in psychiatry: Expert consensus. <i>World Journal of Biological Psychiatry</i> , 2016 , 17, 86-128	3.8	146
213	Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. <i>Revista De Psiquiatría Y Salud Mental</i> , 2016 , 9, 158-73	2.7	33
212	Age at First Episode Modulates Diagnosis-Related Structural Brain Abnormalities in Psychosis. <i>Schizophrenia Bulletin</i> , 2016 , 42, 344-57	1.3	42
211	BDNF and NGF Signalling in Early Phases of Psychosis: Relationship With Inflammation and Response to Antipsychotics After 1 Year. <i>Schizophrenia Bulletin</i> , 2016 , 42, 142-51	1.3	37
210	Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History. <i>PLoS ONE</i> , 2016 , 11, e0160949	3.7	15
209	Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2016 , 41, E46-55	4.5	41
208	Electroconvulsive Therapy Practice in Spain: A National Survey. <i>Journal of ECT</i> , 2016 , 32, 55-61	2	15
207	Association of birth weight and the development of antipsychotic induced adiposity in individuals with treatment resistant schizophrenia. <i>European Neuropsychopharmacology</i> , 2016 , 26, 972-8	1.2	7
206	The oestrogen dysfunction hypothesis in schizophrenia: The need for an integrative approach to treat postmenopausal women. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016 , 50, 1207-1208	2.6	4
205	Detection and management of agitation in psychiatry: A Delphi expert consensus study. <i>European Psychiatry</i> , 2016 , 33, S170-S170	6	3
204	Three-month paliperidone palmitate - a new treatment option for schizophrenia. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 899-904	3.8	7
203	Utilizaci3n de olanzapina en el tratamiento de la esquizofrenia y el trastorno bipolar. <i>Psiquiatría Biológica</i> , 2016 , 23, 4-22	0.2	2
202	Cortical thickness in regions of frontal and temporal lobes is associated with responsiveness to cognitive remediation therapy in schizophrenia. <i>Schizophrenia Research</i> , 2016 , 171, 110-6	3.6	22

201	Abnormal glycemic homeostasis at the onset of serious mental illnesses: A common pathway. <i>Psychoneuroendocrinology</i> , 2016 , 67, 70-5	5	38
200	Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders. <i>European Psychiatry</i> , 2016 , 38, 61-69	6	12
199	Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2016 , 9, 158-173	0.2	6
198	Risk factor assessment and counselling for 12 months reduces metabolic and cardiovascular risk in overweight or obese patients with schizophrenia spectrum disorders: The CRESSOB study. <i>Actas Espanolas De Psiquiatria</i> , 2016 , 44, 20-9	0.7	7
197	Antipsychotic response in delusional disorder and schizophrenia: a prospective cohort study. <i>Actas Espanolas De Psiquiatria</i> , 2016 , 44, 125-35	0.7	11
196	Long-term effectiveness of electroconvulsive therapy in adolescents with schizophrenia spectrum disorders. <i>European Child and Adolescent Psychiatry</i> , 2015 , 24, 517-24	5.5	10
195	Dignifying Electroconvulsive Therapy based on evidence. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2015 , 8, 51-54	0.2	1
194	Building up careers in translational neuroscience and mental health research: Education and training in the Centre for Biomedical Research in Mental Health. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2015 , 8, 65-74	0.2	1
193	Validation of the Spanish version of the Clinical Assessment for Negative Symptoms (CAINS). <i>Schizophrenia Research</i> , 2015 , 166, 104-9	3.6	38
192	Inflammation in schizophrenia: A question of balance. <i>Neuroscience and Biobehavioral Reviews</i> , 2015 , 55, 612-26	9	122
191	Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study. <i>Schizophrenia Research</i> , 2015 , 164, 65-73	3.6	75
190	Electroconvulsive therapy practice in Catalonia: a survey study comparing data from 1993 and 2010. <i>Journal of ECT</i> , 2015 , 31, 43-9	2	5
189	Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naïve first-episode schizophrenia and healthy controls. <i>Translational Psychiatry</i> , 2015 , 5, e626	8.6	16
188	Búsqueda De Nuevos Biomarcadores De La Cognición En Esquizofrenia. <i>Schizophrenia Research: Cognition</i> , 2015 , 2, 196-203	2.8	
187	The negative syndrome of schizophrenia: three -underlying components are better than two. <i>Schizophrenia Research</i> , 2015 , 166, 115-8	3.6	15
186	Impacto de la modificación de la bioapariencia de los antipsicóticos sobre la adherencia terapéutica en los pacientes con esquizofrenia: Estudio CAPS. <i>Psiquiatria Biologica</i> , 2015 , 22, 1-4	0.2	1
185	Therapeutic approach to delusional disorder based on psychopathological complexity: proposal for a decision model. <i>Journal of Clinical Psychopharmacology</i> , 2015 , 35, 201-2	1.7	8
184	Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review. <i>Patient Preference and Adherence</i> , 2015 , 9, 695-706	2.4	18

183	Delusional Disorder over the Reproductive Life Span: The Potential Influence of Menopause on the Clinical Course. <i>Schizophrenia Research and Treatment</i> , 2015 , 2015, 979605	0.6	6
182	The search for new biomarkers for cognition in schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2015 , 2, 172-178	2.8	19
181	Patients' Opinions About Electroconvulsive Therapy: What Do Adolescents with Schizophrenia Spectrum Disorders Think?. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015 , 25, 641-8	2.9	13
180	Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway. <i>European Neuropsychopharmacology</i> , 2015 , 25, 51-9	1.2	24
179	Disability in bipolar I disorder: the 36-item World Health Organization Disability Assessment Schedule 2.0. <i>Journal of Affective Disorders</i> , 2015 , 174, 353-60	6.6	26
178	Building up careers in translational neuroscience and mental health research: Education and training in the Centre for Biomedical Research in Mental Health. <i>Revista De Psiquiatria Y Salud Mental</i> , 2015 , 8, 65-74	2.7	5
177	Network analysis of gene expression in peripheral blood identifies mTOR and NF- κ B pathways involved in antipsychotic-induced extrapyramidal symptoms. <i>Pharmacogenomics Journal</i> , 2015 , 15, 452-60	3.5	17
176	"Is bipolar disorder an endocrine condition?" Glucose abnormalities in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2014 , 129, 73-4	6.5	12
175	Comparison of serum BDNF levels in deficit and nondeficit chronic schizophrenia and healthy controls. <i>Psychiatry Research</i> , 2014 , 220, 197-200	9.9	15
174	Cognitive remediation therapy in adolescents with early-onset schizophrenia: a randomized controlled trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014 , 53, 859-68	7.2	44
173	Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case-control sample from Spain. <i>Schizophrenia Research</i> , 2014 , 159, 107-13	3.6	27
172	Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-naïve first-episode schizophrenia patients. <i>Journal of Psychiatric Research</i> , 2014 , 48, 94-101	5.2	31
171	Spanish adaptation and validation of the Brief Negative Symptoms Scale. <i>Comprehensive Psychiatry</i> , 2014 , 55, 1726-9	7.3	45
170	What have we learned from research into first-episode psychosis?. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2014 , 7, 61-63	0.2	
169	A descriptive retrospective study of the treatment and outpatient service use in a clinical group of delusional disorder patients. <i>Revista De Psiquiatria Y Salud Mental</i> , 2014 , 7, 64-71	2.7	11
168	Pro-/antiinflammatory dysregulation in early psychosis: results from a 1-year follow-up study. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 18,	5.8	18
167	Brain metabolism during hallucination-like auditory stimulation in schizophrenia. <i>PLoS ONE</i> , 2014 , 9, e84987	3.7	19
166	Awareness of illness and suicidal behavior in delusional disorder patients. <i>Revista De Psiquiatria Clinica</i> , 2014 , 41, 156-158	0.8	3

165	Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. <i>Schizophrenia Bulletin</i> , 2014 , 40, 376-87	1.3	116
164	Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial. <i>Pharmacogenomics</i> , 2014 , 15, 17-28	2.6	10
163	Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. <i>Schizophrenia Bulletin</i> , 2014 , 40, 729-36	1.3	186
162	Hippocampal abnormalities and age in chronic schizophrenia: morphometric study across the adult lifespan. <i>British Journal of Psychiatry</i> , 2014 , 205, 369-75	5.4	17
161	Antipsychotic switching in bipolar disorders: a systematic review. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 17, 497-507	5.8	25
160	Effectiveness of long-acting injectable antipsychotics in delusional disorders with nonprominent hallucinations and without hallucinations. <i>International Clinical Psychopharmacology</i> , 2014 , 29, 177-80	2.2	16
159	Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2014 , 75, 608-15	4.6	11
158	Schizophrenia and cerebrovascular disease. A description of a series and bibliographic review. <i>Actas Espanolas De Psiquiatria</i> , 2014 , 42, 74-82	0.7	3
157	The screen for cognitive impairment in psychiatry: diagnostic-specific standardization in psychiatric ill patients. <i>BMC Psychiatry</i> , 2013 , 13, 127	4.2	30
156	Assessment of real-world daily-living skills in early-onset schizophrenia through the Life Skills Profile scale. <i>Schizophrenia Research</i> , 2013 , 145, 95-100	3.6	7
155	Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). <i>Revista De Psiquiatria Y Salud Mental</i> , 2013 , 6, 4-16	2.7	78
154	Should obesity be a limiting factor for clozapine treatment?. <i>Revista De Psiquiatria Y Salud Mental</i> , 2013 , 6, 75-9	2.7	4
153	Functional analysis of gene expression in risperidone treated cells provide new insights in molecular mechanism and new candidate genes for pharmacogenetic studies. <i>European Neuropsychopharmacology</i> , 2013 , 23, 329-37	1.2	14
152	Should obesity be a limiting factor for clozapine treatment?. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2013 , 6, 75-79	0.2	1
151	Inferior frontal and insular cortical thinning is related to dysfunctional brain activation/deactivation during working memory task in schizophrenic patients. <i>Psychiatry Research - Neuroimaging</i> , 2013 , 214, 94-101	2.9	19
150	Brain effects of cognitive remediation therapy in schizophrenia: a structural and functional neuroimaging study. <i>Biological Psychiatry</i> , 2013 , 73, 1015-23	7.9	135
149	Abnormal glucose tolerance, white blood cell count, and telomere length in newly diagnosed, antidepressant-naïve patients with depression. <i>Brain, Behavior, and Immunity</i> , 2013 , 28, 49-53	16.6	60
148	Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2013 , 6, 4-16	0.2	3

147	Screening for substance use disorders in first-episode psychosis: implications for readmission. <i>Schizophrenia Research</i> , 2013 , 146, 125-31	3.6	21
146	El papel del placebo en ensayos clínicos en esquizofrenia. <i>Psiquiatría Biológica</i> , 2013 , 20, 63-69	0.2	
145	Eficacia de los ácidos grasos omega-3 como tratamiento suplementario en la esquizofrenia. <i>Psiquiatría Biológica</i> , 2013 , 20, 8-13	0.2	
144	Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. <i>Human Psychopharmacology</i> , 2013 , 28, 586-93	2.3	14
143	Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers. <i>Pharmacogenomics</i> , 2013 , 14, 1551-63	2.6	11
142	Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients. <i>Nordic Journal of Psychiatry</i> , 2013 , 67, 22-9	2.3	18
141	Peripheral endocannabinoid system dysregulation in first-episode psychosis. <i>Neuropsychopharmacology</i> , 2013 , 38, 2568-77	8.7	61
140	Factors associated with relapse in patients with schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> , 2013 , 17, 2-9	2.4	35
139	Left amygdalar activation in deficit syndrome compared with non-deficit subjects with schizophrenia during the control task in a facial emotion recognition paradigm. <i>Psychiatry Research - Neuroimaging</i> , 2012 , 203, 109-10	2.9	2
138	Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features. <i>Psychiatry Research</i> , 2012 , 198, 212-5	9.9	61
137	Clozapine and agranulocytosis in Spain: Do we have a safer population? A 5-year haematologic follow-up. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2012 , 5, 37-42	0.2	
136	Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012 , 36, 71-7	5.5	35
135	Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012 , 36, 245-50	5.5	13
134	Sulforaphane protects SK-N-SH cells against antipsychotic-induced oxidative stress. <i>Fundamental and Clinical Pharmacology</i> , 2012 , 26, 712-21	3.1	19
133	Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. <i>Pharmacogenomics</i> , 2012 , 13, 1773-82	2.6	15
132	Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis. <i>Schizophrenia Research</i> , 2012 , 134, 16-9	3.6	61
131	Utility of the World Health Organization Disability Assessment Schedule II in schizophrenia. <i>Schizophrenia Research</i> , 2012 , 138, 240-7	3.6	43
130	Antipsychotic polypharmacy in a regional health service: a population-based study. <i>BMC Psychiatry</i> , 2012 , 12, 42	4.2	27

129	Ziprasidone versus Olanzapine in the weight gain associated with the treatment of schizophrenia: A six-month double-blind randomized parallel group study. <i>European Journal of Psychiatry</i> , 2012 , 26, 248-259	1.9	4
128	Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. <i>Pharmacogenomics Journal</i> , 2012 , 12, 255-9	3.5	29
127	Processing speed and executive functions predict real-world everyday living skills in adolescents with early-onset schizophrenia. <i>European Child and Adolescent Psychiatry</i> , 2012 , 21, 315-26	5.5	21
126	Is abnormal glucose tolerance in antipsychotic-naïve patients with nonaffective psychosis confounded by poor health habits?. <i>Schizophrenia Bulletin</i> , 2012 , 38, 280-4	1.3	61
125	Use of electroconvulsive therapy in Parkinson disease with residual axial symptoms partially unresponsive to L-dopa: a pilot study. <i>Journal of ECT</i> , 2012 , 28, 87-91	2	16
124	Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: is it a safe and effective combination?. <i>Journal of Clinical Psychopharmacology</i> , 2012 , 32, 756-66	1.7	24
123	The integration of cognitive remediation therapy into the whole psychosocial rehabilitation process: an evidence-based and person-centered approach. <i>Rehabilitation Research and Practice</i> , 2012 , 2012, 386895	1.2	9
122	Spanish adaptation of the Beck Cognitive Insight Scale (BCIS) for schizophrenia. <i>Actas Espanolas De Psiquiatria</i> , 2012 , 40, 2-9	0.7	18
121	Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry. <i>Revista De Psiquiatria Y Salud Mental</i> , 2011 , 4, 150-68	2.7	21
120	Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2011 , 4, 150-168	0.2	1
119	Systematic review of the Genomewide Association Studies (GWAS) in schizophrenia. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2011 , 4, 218-227	0.2	1
118	Brief cognitive assessment instruments in schizophrenia and bipolar patients, and healthy control subjects: a comparison study between the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) and the Screen for Cognitive Impairment in Psychiatry (SCIP). <i>Schizophrenia Research</i> , 2011 , 129, 127-32	3.6	29
117	Comparison between young siblings and offspring of subjects with schizophrenia: clinical and neuropsychological characteristics. <i>Schizophrenia Research</i> , 2011 , 131, 35-42	3.6	20
116	Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls. <i>European Psychiatry</i> , 2011 , 26, 69-73	6	51
115	Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients. <i>European Neuropsychopharmacology</i> , 2011 , 21, 294-9	1.2	9
114	Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics. <i>Patient Preference and Adherence</i> , 2011 , 5, 601-10	2.4	3
113	Metabolic effects of olanzapine in patients with newly diagnosed psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 154-9	1.7	34
112	Testosterone in newly diagnosed, antipsychotic-naïve men with nonaffective psychosis: a test of the accelerated aging hypothesis. <i>Psychosomatic Medicine</i> , 2011 , 73, 643-7	3.7	35

111	A 4-year dopamine transporter (DAT) imaging study in neuroleptic-naïve first episode schizophrenia patients. <i>Psychiatry Research - Neuroimaging</i> , 2011 , 194, 79-84	2.9	11
110	QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment. <i>Human Psychopharmacology</i> , 2011 , 26, 397-403	2.3	14
109	Non-adherence to oral antipsychotics in schizophrenia: Relapse and therapeutic strategies in a 12-month observational study. <i>European Psychiatry</i> , 2011 , 26, 1362-1362	6	1
108	Two-year follow-up of cognitive functions in schizophrenia spectrum disorders of adolescent patients treated with electroconvulsive therapy. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011 , 21, 611-9	2.9	24
107	Differential brain glucose metabolic patterns in antipsychotic-naïve first-episode schizophrenia with and without auditory verbal hallucinations. <i>Journal of Psychiatry and Neuroscience</i> , 2011 , 36, 312-214.5	4.5	24
106	Lack of association between schizophrenia and polymorphisms in dopamine metabolism and transport genes. <i>Fundamental and Clinical Pharmacology</i> , 2010 , 24, 741-7	3.1	9
105	Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders. <i>Pharmacogenomics</i> , 2010 , 11, 1725-31	2.6	12
104	Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S). <i>Schizophrenia Research</i> , 2010 , 116, 243-51	3.6	40
103	Relationship between clinical and neuropsychological characteristics in child and adolescent first degree relatives of subjects with schizophrenia. <i>Schizophrenia Research</i> , 2010 , 116, 159-67	3.6	21
102	Anterior cingulate and paracingulate sulci morphology in patients with schizophrenia. <i>Schizophrenia Research</i> , 2010 , 121, 66-74	3.6	15
101	Clinical experience using electroconvulsive therapy in adolescents with schizophrenia spectrum disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010 , 20, 205-9	2.9	26
100	Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes. <i>Psychiatry Research</i> , 2010 , 175, 173-5	9.9	8
99	Cholesterol and triglycerides in antipsychotic-naïve patients with nonaffective psychosis. <i>Psychiatry Research</i> , 2010 , 178, 559-61	9.9	10
98	18FDG PET study of amygdalar activity during facial emotion recognition in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010 , 260, 69-76	5.1	26
97	A functional variant provided further evidence for the association of ARVCF with schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010 , 153B, 1052-9	3.5	7
96	Metabolic profile of antipsychotic-naïve individuals with non-affective psychosis. <i>British Journal of Psychiatry</i> , 2009 , 194, 434-8	5.4	193
95	Telomere length and pulse pressure in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis. <i>Schizophrenia Bulletin</i> , 2009 , 35, 437-42	1.3	82
94	A continuous emotional task activates the left amygdala in healthy volunteers: (18)FDG PET study. <i>Psychiatry Research - Neuroimaging</i> , 2009 , 171, 199-206	2.9	8

93	A voxel-based diffusion tensor imaging study of temporal white matter in patients with schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2009 , 171, 166-76	2.9	27
92	Hippocampal underactivation in an fMRI study of word and face memory recognition in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009 , 259, 203-11	5.1	18
91	Stem cell signaling in newly diagnosed, antipsychotic-naive subjects with nonaffective psychosis. <i>Molecular Psychiatry</i> , 2009 , 14, 989-91	15.1	13
90	A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. <i>Pharmacogenomics Journal</i> , 2009 , 9, 404-10	3.5	37
89	Adaptation and validation of the quality-of-life scale: Satisfaction with Life Domains Scale by Baker and Intagliata. <i>Comprehensive Psychiatry</i> , 2009 , 50, 76-80	7.3	13
88	Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients. <i>Psychiatry Research</i> , 2009 , 168, 110-8	9.9	15
87	Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with schizophrenia in a Spanish population. <i>Psychiatry Research</i> , 2009 , 165, 175-80	9.9	30
86	Plasma homovanillic acid in adolescents with bulimia nervosa. <i>Psychiatry Research</i> , 2009 , 170, 241-4	9.9	3
85	ARVCF single marker and haplotypic association with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009 , 33, 1064-9	5.5	14
84	Differences in glucose tolerance between deficit and nondeficit schizophrenia. <i>Schizophrenia Research</i> , 2009 , 107, 122-7	3.6	53
83	Progressive gray matter changes in first episode schizophrenia: a 4-year longitudinal magnetic resonance study using VBM. <i>Schizophrenia Research</i> , 2009 , 114, 136-43	3.6	84
82	Adaptation and validation of the Spanish version of the Strauss and Carpenter Prognostic Scale for Schizophrenia. <i>Revista De Psiquiatría Y Salud Mental</i> , 2009 , 2, 150-9	2.7	9
81	Spanish Adaptation and Validation of the Strauss-Carpenter Outcome Scale for Schizophrenia. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2009 , 2, 150-159	0.2	
80	Clinical usefulness of the screen for cognitive impairment in psychiatry (SCIP-S) scale in patients with type I bipolar disorder. <i>Health and Quality of Life Outcomes</i> , 2009 , 7, 28	3	28
79	Prevalence of Metabolic Syndrome in Spanish Patients with Schizophrenia and Overweight. <i>European Psychiatry</i> , 2009 , 24, 1-1	6	
78	Cannabis use and age of diagnosis of schizophrenia. <i>European Psychiatry</i> , 2009 , 24, 282-6	6	32
77	Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. <i>European Psychiatry</i> , 2009 , 24, 431-41	6	41
76	Electroconvulsive therapy in early adolescents with schizophrenia spectrum disorders. <i>Journal of ECT</i> , 2009 , 25, 278-9	2	9

75	Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008 , 35, 807-11	3	30
74	Psychopathological and nutritional correlates of plasma homovanillic acid in adolescents with anorexia nervosa. <i>Journal of Psychiatric Research</i> , 2008 , 42, 213-20	5.2	11
73	Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): psychometric properties of a brief scale for cognitive evaluation in schizophrenia. <i>Schizophrenia Research</i> , 2008 , 99, 139-48	3.6	60
72	Parental history of type 2 diabetes in patients with nonaffective psychosis. <i>Schizophrenia Research</i> , 2008 , 98, 302-6	3.6	66
71	Glucose abnormalities in the siblings of people with schizophrenia. <i>Schizophrenia Research</i> , 2008 , 103, 110-3	3.6	75
70	Somatosensory amplification in schizophrenia is associated with preserved neuropsychological function. <i>Revista De Psiquiatria Y Salud Mental</i> , 2008 , 1, 3-9	2.7	2
69	Cognitive functions after only one ECT session: a controlled study. <i>Psychiatry Research</i> , 2008 , 158, 389-94	4.9	11
68	Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and -141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. <i>Psychiatry Research</i> , 2008 , 161, 131-41	9.9	36
67	Electroconvulsive therapy in the treatment of mixed states in bipolar disorder. <i>European Psychiatry</i> , 2008 , 23, 53-6	6	44
66	Association of A/G polymorphism in intron 13 of the monoamine oxidase B gene with schizophrenia in a Spanish population. <i>Neuropsychobiology</i> , 2008 , 58, 65-70	4	18
65	Fluorodeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after remission and during linguistic-auditory activation. <i>Nuclear Medicine Communications</i> , 2008 , 29, 894-900	1.6	25
64	Cerebellar deficits in schizophrenia are associated with executive dysfunction. <i>NeuroReport</i> , 2008 , 19, 1513-7	1.7	29
63	A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2008 , 23, 138-49	2.2	11
62	-141C Ins/Del polymorphism of the dopamine D2 receptor gene is associated with schizophrenia in a Spanish population. <i>Psychiatric Genetics</i> , 2008 , 18, 122-7	2.9	20
61	A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). <i>Current Medical Research and Opinion</i> , 2007 , 23, 2313-23	2.5	24
60	Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. <i>Schizophrenia Research</i> , 2007 , 90, 115-22	3.6	38
59	Schizophrenia and frontal cortex: where does it fail?. <i>Schizophrenia Research</i> , 2007 , 91, 73-81	3.6	19
58	Left posterior hippocampal density reduction using VBM and stereological MRI procedures in schizophrenia. <i>Schizophrenia Research</i> , 2007 , 96, 62-71	3.6	33

57	Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2007 , 34, 992-7	3	20
56	Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. <i>Psychopharmacology</i> , 2007 , 191, 805-14	7	43
55	Oxcarbazepine in the treatment of bipolar and schizoaffective disorders. <i>Expert Review of Neurotherapeutics</i> , 2007 , 7, 617-26	4.3	21
54	Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 284-8	1.7	57
53	Cost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain. <i>Clinical Drug Investigation</i> , 2006 , 26, 447-57	3.2	18
52	Tratamiento de la manía con terapia electroconvulsiva. <i>Psiquiatria Biologica</i> , 2006 , 13, 61-66	0.2	
51	Standardized remission criteria in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2006 , 113, 91-5	6.5	189
50	Neuroleptic malignant syndrome associated with risperidone in a male with early-onset schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2005 , 15, 844-5	2.9	9
49	Volume changes in gray matter in first-episode neuroleptic-naive schizophrenic patients treated with risperidone. <i>Journal of Clinical Psychopharmacology</i> , 2005 , 25, 111-7	1.7	68
48	Excellent review of psychotropic drug-induced torsade de pointes. <i>Acta Psychiatrica Scandinavica</i> , 2005 , 112, 78; author reply 78-9	6.5	
47	The highest intentional ziprasidone overdose was not fatal. <i>Acta Psychiatrica Scandinavica</i> , 2005 , 112, 79-80; author reply 80	6.5	3
46	Ziprasidone overdose: cases recorded in the database of Pfizer-Spain and literature review. <i>Pharmacotherapy</i> , 2005 , 25, 1660-5	5.8	11
45	The effect of quetiapine on aggression and hostility in patients with schizophrenia. <i>Human Psychopharmacology</i> , 2005 , 20, 237-41	2.3	30
44	Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. <i>Psychopharmacology</i> , 2005 , 181, 401-6	4.7	32
43	Absence of additional cognitive impairment in schizophrenia patients during maintenance electroconvulsive therapy. <i>Schizophrenia Bulletin</i> , 2004 , 30, 185-9	1.3	28
42	Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study. <i>Psychiatry Research - Neuroimaging</i> , 2004 , 130, 79-84	2.9	12
41	Striatal dopamine D2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: an 123I-IBZM-SPECT study. <i>Psychopharmacology</i> , 2004 , 172, 165-9	4.7	7
40	ECT in disorganized schizophrenia. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2004 , 43, 1191-2	7.2	4

39	Decreased cerebral activation during CPT performance: structural and functional deficits in schizophrenic patients. <i>NeuroImage</i> , 2004 , 21, 840-7	7.9	99
38	Cognitive status of psychiatric patients under maintenance electroconvulsive therapy: a one-year longitudinal study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2004 , 16, 465-71	2.7	21
37	No brain perfusion impairment at long-term follow-up in elderly patients treated with electroconvulsive therapy for major depression. <i>Journal of ECT</i> , 2004 , 20, 89-93	2	11
36	Frontal cerebral perfusion after antidepressant drug treatment versus ECT in elderly patients with major depression: a 12-month follow-up control study. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 656-61	4.6	20
35	Pattern of cognitive dysfunction in depressive patients during maintenance electroconvulsive therapy. <i>Psychological Medicine</i> , 2003 , 33, 345-50	6.9	23
34	Paracingulate sulcus morphology in men with early-onset schizophrenia. <i>British Journal of Psychiatry</i> , 2003 , 182, 228-32	5.4	62
33	Cognitive mechanisms, psychosocial functioning, and neurocognitive rehabilitation in schizophrenia. <i>Schizophrenia Research</i> , 2003 , 63, 219-27	3.6	49
32	Sustained attention impairment correlates to gray matter decreases in first episode neuroleptic-naive schizophrenic patients. <i>NeuroImage</i> , 2003 , 19, 365-75	7.9	155
31	Basal ganglia N-acetylaspartate correlates with the performance in the procedural task Tower of Hanoi in neuroleptic-naive schizophrenic patients. <i>Neuroscience Letters</i> , 2003 , 347, 97-100	3.3	28
30	Suicidal ideation, psychiatric disorder, and medical illness in a community epidemiological study. <i>Suicide and Life-Threatening Behavior</i> , 2001 , 31, 207-13	3.9	29
29	Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. <i>American Journal of Psychiatry</i> , 2001 , 158, 1149-51	11.9	218
28	Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint. <i>Psychiatry Research - Neuroimaging</i> , 2001 , 107, 87-97	2.9	20
27	Mental disorders and medical conditions. A community study in a small island in Spain. <i>Journal of Psychosomatic Research</i> , 2001 , 50, 39-44	4.1	9
26	Comparative hemodynamic effects of urapidil and labetalol after electroconvulsive therapy. <i>Journal of ECT</i> , 2001 , 17, 275-9	2	10
25	Fluoxetine in the prevention of depressive recurrences: a double-blind study. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 417-24	1.7	35
24	Subtypes of memory dysfunction associated with ECT: characteristics and neurobiological bases. <i>Journal of ECT</i> , 2001 , 17, 129-35	2	53
23	Topiramate for clozapine-induced seizures. <i>American Journal of Psychiatry</i> , 2001 , 158, 968-9	11.9	27
22	"Hyperacusis" and origins of lowered sound tolerance. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2000 , 12, 117-9	2.7	13

21	Psychopathology and wisconsin card sorting test performance in young unmedicated schizophrenic patients. <i>Psychopathology</i> , 2000 , 33, 14-8	3.4	14
20	Brain perfusion and neuropsychological changes in schizophrenic patients after cognitive rehabilitation. <i>Psychiatry Research - Neuroimaging</i> , 2000 , 98, 127-32	2.9	18
19	Seizure activity and safety in combined treatment with venlafaxine and ECT: a pilot study. <i>Journal of ECT</i> , 2000 , 16, 38-42	2	24
18	Repetitive transcranial magnetic stimulation in the treatment of chronic negative schizophrenia: a pilot study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 67, 129-30	5.5	62
17	Mental disorders on the island of Formentera: prevalence in general population using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN). <i>Social Psychiatry and Psychiatric Epidemiology</i> , 1999 , 34, 410-5	4.5	14
16	Role of the cingulate gyrus during the Wisconsin Card Sorting Test: a single photon emission computed tomography study in normal volunteers. <i>Psychiatry Research - Neuroimaging</i> , 1998 , 83, 67-74	2.9	19
15	The resting and activation issue of hypofrontality: a single photon emission computed tomography study in neuroleptic-naive and neuroleptic-free schizophrenic female patients. <i>Biological Psychiatry</i> , 1998 , 44, 787-90	7.9	34
14	Role of Cingulate Gyrus during Wisconsin Card Sorting Test: A Single Photon Emission Computed Tomography (Spect) Study. <i>Key Topics in Brain Research</i> , 1997 , 119-123		
13	The relationship between plasma haloperidol concentrations and clinical results. <i>Archives of General Psychiatry</i> , 1996 , 53, 1167-9		5
12	Regional cerebral blood flow pattern in normal young and aged volunteers: a 99mTc-HMPAO SPET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996 , 23, 1329-37		73
11	Baseline, visual deprivation and visual stimulation 99Tcm-HMPAO-related changes in visual cortex can be detected with a single-head SPET system. <i>Nuclear Medicine Communications</i> , 1996 , 17, 480-4	1.6	6
10	Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: a resting and activation SPECT study. <i>Psychiatry Research - Neuroimaging</i> , 1994 , 55, 131-9	2.9	62
9	Positive versus negative symptoms in schizophrenia: response to haloperidol. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1994 , 18, 155-64	5.5	10
8	Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-naive patients with acute disease. <i>Journal of Nuclear Medicine</i> , 1994 , 35, 935-41	8.9	105
7	Hypophyseal response to ECT: a higher and faster vasopressin peak. <i>Biological Psychiatry</i> , 1993 , 33, 670-7	7.9	5
6	Schizophrenia, Obsessive-Compulsive Disorder, and Tourette's Syndrome: A Case of Triple Comorbidity. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1993 , 5, 108-108	2.7	3
5	Antidepressant-induced mania in obsessive-compulsive disorder. <i>American Journal of Psychiatry</i> , 1992 , 149, 1282-3	11.9	6
4	Coronary heart disease and psychological variables: is Type A enough to increase the risk?. <i>Personality and Individual Differences</i> , 1987 , 8, 733-736	3.3	4

3	Jumping To Conclusions, General Intelligence, And Psychosis Liability: Findings From The Multi-Centre EU-GEI Case-Control Study		1
2	The independent and combined influence of schizophrenia polygenic risk score and heavy cannabis use on risk for psychotic disorder: A case-control analysis from the EUGEI study.		2
1	Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis: the EU-GEI study. <i>Psychological Medicine</i> ,1-9	6.9	1